Table 4.

Encapsulated substances, including commercial drugs and natural compounds, for the treatments of fungal infections.

Drug/compound	Fungal infection	Findings	References
Amphotericin B (AmB)	Systemic fungal infections and leishmaniasis	Higher accumulation values in human skin of AmB nanoliposomes and lower MIC values than as commercial product AmBisome. Deeper penetration in epithelial layers.	Perez et al., 2016
Bexarotene	Psoriasis	Reversion of psoriasis. Safety compatibility profile. Controlled release for over a period of 24 h. High percentage of entrapment efficiency.	Saka et al., 2020
Econazole	Tinea pedis	Superiority in clinical and mycological parameters of efficacy. Better tolerability compared witheconazole cream and clotrimazole cream treatment groups.	Korting et al., 1997
Fluconazole	Aspergillosis	Nano-fluconazole had better antifungal effects than the common form of drug on A. flavus and A. fumigatus species. Controlled and sustained release. Chemical stability enhancement.	Sarrafha et al., 2018
Fluconazole	Candida albicanis	Controlled particle size and appropriate drug loading. Superior Fluconazole entrapment and lower constant drug release compared to nanoethosome formulation. Potential application to prevent fungal biofilm formation	Zandi et al., 2018
Voriconazole (VCZ)	Candida albicanis	Effective, biocompatible, biodegradable and safe antifungal for intravenous delivery. Protection from premature metabolism.	Veloso et al., 2018